Trends in the Epidemiology and Treatment of Pediatric-Onset Multiple Sclerosis in Alberta, Canada

BACKGROUND: Fingolimod became the first disease-modifying therapy approved by Health Canada for pediatric multiple sclerosis in 2018, but the impact of that approval on treatment patterns in Canada is unknown. The aim of this study was to describe trends in the epidemiology and treatment of pediatri...

Descripción completa

Detalles Bibliográficos
Autores principales: Yearwood, Camille, Wilbur, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338710/
https://www.ncbi.nlm.nih.gov/pubmed/37203134
http://dx.doi.org/10.1177/08830738231176588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338710/
https://www.ncbi.nlm.nih.gov/pubmed/37203134
http://dx.doi.org/10.1177/08830738231176588

Ejemplares similares